Caitong International Asset Management Co., LTD Allogene Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $144 Billion
- Q3 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 24,047 shares of ALLO stock, worth $29,577. This represents 0.02% of its overall portfolio holdings.
Number of Shares
24,047
Previous 448
5267.63%
Holding current value
$29,577
Previous $506,000
5792.89%
% of portfolio
0.02%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ALLO
# of Institutions
182Shares Held
138MCall Options Held
76.6KPut Options Held
36.2K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23 Million1.5% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.02MShares$11.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA7.08MShares$8.71 Million0.01% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $177M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...